CDK4,6 Inhibitors in Breast Cancer

CE / CME

Experts Answer Your Questions on CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
Credits Available

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Released: July 05, 2024

Expiration: July 04, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following CDK4/6 inhibitors plus ET has demonstrated a statistically significant improvement in median OS across multiple phase III trials as first-line therapy in metastatic HR-positive/HER2-negative breast cancer?